Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB PharmaS. A.; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.19 Increased by +40.63% | -0.19 |
| Mar 4, 24 | -0.22 Increased by +31.25% | -0.21 Decreased by -4.76% |
| Nov 7, 23 | -0.24 Increased by +22.58% | -0.20 Decreased by -20.00% |
| Aug 8, 23 | -0.27 Increased by +68.24% | -0.28 Increased by +3.57% |
| May 9, 23 | -0.32 Increased by +34.69% | -0.25 Decreased by -28.00% |
| Feb 28, 23 | -0.32 Increased by +59.49% | -0.45 Increased by +28.89% |
| Nov 3, 22 | -0.31 Increased by +55.71% | -0.45 Increased by +31.11% |
| Aug 4, 22 | -0.85 Decreased by -23.19% | -0.94 Increased by +9.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 24.14 M Increased by +2.20% | -45.84 M Increased by +22.37% | Decreased by -189.85% Increased by +24.04% |
| Jun 30, 23 | 20.50 M Decreased by -5.03% | -51.12 M Increased by +67.86% | Decreased by -249.39% Increased by +66.16% |
| Mar 31, 23 | 21.59 M Decreased by -13.00% | -137.02 M Decreased by -51.58% | Decreased by -634.52% Decreased by -74.24% |
| Dec 31, 22 | 22.02 M Decreased by -11.94% | -59.69 M Increased by +59.02% | Decreased by -271.03% Increased by +53.46% |
| Sep 30, 22 | 23.63 M Decreased by -5.20% | -59.05 M Increased by +54.47% | Decreased by -249.94% Increased by +51.98% |
| Jun 30, 22 | 21.59 M Decreased by -23.81% | -159.07 M Decreased by -26.73% | Decreased by -736.94% Decreased by -66.33% |
| Mar 31, 22 | 24.82 M Increased by +4.97% | -90.39 M Increased by +26.49% | Decreased by -364.16% Increased by +29.97% |
| Dec 31, 21 | 25.01 M Increased by +6.59% | -145.65 M Decreased by -24.27% | Decreased by -582.37% Decreased by -16.58% |